BGB-11417-103 Trial

Molecule: Sonrotoclax

BGB-11417-103 (NCT04771130) is a Phase 1b/2, open-label, dose-finding, and expansion study of sonrotoclax in patients with myeloid malignancies.

Reading
6 Dec 2024

BGB-11417-102 (NCT04883957) is a Phase 1 trial of sonrotoclax in adult patients with mature B-cell malignancies.

Reading
6 Dec 2024

BGB-11417-101 (NCT04277637) is a Phase 1a/1b, open-label, dose-escalation and expansion trial of sonrotoclax in patients with mature B-cell malignancies.

Reading
6 Dec 2024

Sonrotoclax is an investigational potent and selective inhibitor of BCL2.

6 Dec 2024

21 Nov 2024